Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Controller General Of India Surinder Singh On India’s Regulatory Overhaul: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Surinder Singh took the mantle of the Drug Controller General of India a few months ago. From being a microbiologist to handling the most important regulatory position in the Indian drug industry, Singh is already confronted with a host of challenges. Overhauling the regulatory system, dealing with vexatious registration issues and advocating for Indian drug industry on global forums, Singh has been working on an extremely tight schedule. Singh took time off from his busy routine and sat down with PharmAsia News' India bureau to discuss India's impending regulatory overhaul (PharmAsia News, Sept. 11, 2008).

You may also be interested in...



Powerful Parliamentary Committee Slams India’s Drug Regulator; Calls For Swift Overhaul

The committee unravels a system full of questionable practices and recommends complete overhaul of India’s drug regulator.

Indian Government In Dilemma As DCGI's Competence Is Questioned Amid Mounting Criticism

MUMBAI - An eerie uncertainty looms over the future of India's highest and most powerful drug authority, the Drug Controller General of India, as the government was challenged last week against its decision to grant a nine-month service term extension to the present incumbent Surinder Singh

Indian Government In Dilemma As DCGI's Competence Is Questioned Amid Mounting Criticism

MUMBAI - An eerie uncertainty looms over the future of India's highest and most powerful drug authority, the Drug Controller General of India, as the government was challenged last week against its decision to grant a nine-month service term extension to the present incumbent Surinder Singh

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066927

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel